BFA
SYRE icon

BlackRock Fund Advisors’s Spyre Therapeutics SYRE Stock Holding History

BlackRock Fund Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$60K Buy
552
+26
+5% +$3.79K ﹤0.01% 3718
2016
Q3 		$84K Buy
526
+85
+19% +$11.8K ﹤0.01% 3651
2016
Q2 		$54K Buy
+441
New +$84.5K ﹤0.01% 3805

Other funds holding SYRE

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock Fund Advisors's SYRE Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Spyre Therapeutics (SYRE) stake by 4.9% in Q4 2016, buying an estimated $3.79K and bringing the position to 552 shares worth $60K. The position accounts for ﹤0.01% of the portfolio, ranked #3718.

BlackRock Fund Advisors first reported a position in SYRE in Q2 2016 and has held it in 3 quarters since. The position peaked at $84K in Q3 2016. 26 funds tracked by Wall St. Rank hold SYRE as of Q4 2016.

  • BlackRock Fund Advisors held 552 shares of Spyre Therapeutics worth $60K as of Q4 2016.
  • BlackRock Fund Advisors bought 26 Spyre Therapeutics shares in Q4 2016, an estimated $3.79K.
  • Spyre Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3718 holding.
  • BlackRock Fund Advisors first reported a position in Spyre Therapeutics in Q2 2016 and has held it in 3 quarters since.
  • BlackRock Fund Advisors's Spyre Therapeutics position peaked at $84K in Q3 2016.
  • 26 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.